Synthesis of cyclohexanone-based cathepsin B inhibitors that interact with both the S and S' binding sites

Tetrahedron Letters

Volumn 39, Issue 45, 1998, Pages 8253-8256

  Conroy, Jeffrey L ^a   Abato, Paul ^a   Ghosh, Mousumi ^a   Austermuhle, Mariana I ^a   Kiefer, Michael R ^a   Seto, Christopher T ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CYCLOHEXANONE; DRUG CARRIER; PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; X RAY CRYSTALLOGRAPHY;

EID: 0032487772     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(98)01783-3     Document Type: Article

References (22)

1. 2. (a) Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, J. G. Cell 1991, 64, 327.
2. (b) Baricos, W. H.; Zhou, Y.; Mason, R. W.; Barrett, A. J. Biochem. J. 1988, 252, 301.
3. 3. Yamashita, D. S.; Smith, W. W.; Zhao, B.; Janson, C. A.; Tomaszek, T. A.; Bossard, M. J.; Levy, M. A.; Oh, H.-J.; Carr, T. J.; Thompson, S. K.; Ijames, C. F.; Carr, S. A.; McQueney, M.; D'Alessio, K. J.; Amegadzie, B. Y.; Manning, C. R.; Abdel-Meguid, S.; DesJarlais, R. L.; Gleason, J. G.; Veber, D. F. J. Am. Chem. Soc. 1997, 119, 11351 and references therein.
4. 4. (a) Miller, D. K. Ann. Rep. Med. Chem. 1996, 31, 249.
5. (b) Schwartz, L. M.; Milligan, C. E. Trends Neurosci. 1996, 19, 555.
6. (c) Nicholson, D. W.; Ali, A.; Thornberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; Munday, N. A.; Raju, S. M.; Smulson, M. E.; Yamin, T.-T.; Yu, V. L.; Miller, D. K. Nature 1995, 376, 37.
7. (d) Nicholson, D. W. Nature Biotech. 14, 297, 1996.
8. 5. For a recent review of cysteine proteases and their inhibitors, see Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 97, 133.
9. 6. Conroy, J. L.; Sanders, T. C.; Seto, C. T. J. Am. Chem. Soc. 1997, 119, 4285.
10. 7. Conroy, J. L.; Seto, C. T. J. Org. Chem. 1998, 63, 2367.
11. 8. For several examples of other reversible cysteine protease inhibitors that extend into both the S and S' binding sites see Hu, L.-Y.; Abeles, R. H. Arch. Biochem. Biophys. 1990, 281, 271, and reference 3.
12. 9. Modeling studies were performed using QUANTA 4.0 molecular modeling software.
13. 10. Turk, D.; Podobnik, M.; Popovic, T.; Katunuma, N.; Bode, W.; Huber, R.; Turk, V. Biochemistry 1995, 34, 4791.
14. 11. Huckin, S. N.; Weiler, L. J. Am. Chem. Soc. 1974, 96, 1082.
15. 13C NMR and high resolution MS.
16. 13. Chan, T. H.; Brook, M, A.; Chaly, T. Synthesis, 1983, 203.
17. 14. Shioiri, T.; Ninomiya, K.; Yamada, S. J. Am. Chem. Soc. 1972, 94, 6203.
18. 15. Fmoc-Pro-Wang resin with a loading of 0.75 mmol/g was purchased from Novabiochem (Product No. 04-12-2000). Three equivalents of carboxylic acid were used in each coupling reaction.
19. 16. The synthesis of compound 18 has been reported in reference 6.
20. 17. Cain, E. N.; Welling, L. L. Tetrahedron Lett. 1975, 1353.
21. 18. Barrett, A. J.; Kirschke, H. Methods Enzymol. 1981, 80, 535.
22. 19. The error in the values of the inhibition constants is approximately ±20%.